These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 301760)

  • 1. Inhibition of ristocetin-induced platelet agglutination by vancomycin.
    Moake JL; Cimo PL; Peterson DM; Roper P; Natelson EA
    Blood; 1977 Sep; 50(3):397-406. PubMed ID: 301760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agglutination of formalin-fixed, platelet-type von Willebrand's disease platelets by human von Willebrand factor.
    Takahashi H; Shibata A
    Thromb Haemost; 1984 Dec; 52(3):267-70. PubMed ID: 6241752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ability of vancomycin-group antibiotics to induce or to inhibit thrombocyte agglutination].
    Rák K; Boda Z; Sztaricskai F
    Antibiotiki; 1980 Aug; 25(8):595-606. PubMed ID: 6250464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.
    Coller BS; Gralnick HR
    J Clin Invest; 1977 Aug; 60(2):302-12. PubMed ID: 17620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination.
    Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL
    J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ristocetin in the diagnosis of von willebrand's disease: a comparison of rate and percent of aggregation with levels of the plasma factor(s) necessary for ristocetin aggregation.
    Dowling SV; Muntz RH; D'Souza S; Ekert H
    Thromb Diath Haemorrh; 1975 Nov; 34(2):465-74. PubMed ID: 1081746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease.
    Green D; Potter EV
    J Lab Clin Med; 1976 Jun; 87(6):976-86. PubMed ID: 778313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agglutination of platelet-type von Willebrand's disease platelets by bovine von Willebrand factor.
    Takahashi H; Shibata A
    Thromb Haemost; 1985 Apr; 53(2):204-7. PubMed ID: 2992113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of von Willebrand factor-induced platelet agglutination by ADP does not result from reduced binding of total von Willebrand factor or its larger multimers.
    Zucker MB; Puszkin EG; Sussman II; Mauss EA
    J Lab Clin Med; 1990 Sep; 116(3):305-14. PubMed ID: 2401846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G.
    Moore A; Ross GD; Nachman RL
    J Clin Invest; 1978 Nov; 62(5):1053-60. PubMed ID: 309473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.
    Coller BS
    J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new mode of defective ristocetin-induced platelet aggregation.
    Baugh RF; Hougie C
    J Lab Clin Med; 1981 Jun; 97(6):864-80. PubMed ID: 6971912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the mechanism of ristocetin-induced platelet agglutination: binding of ristocetin to platelets.
    Jenkins CS; Clemetson KJ; Lüscher EF
    J Lab Clin Med; 1979 Feb; 93(2):220-31. PubMed ID: 311800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family studies of patients with reduced ristocetin aggregation and abnormalities of factor VIII and/or platelet function.
    Ekert H; Ananthakrishnan R; Muntz RH; Dowling S; D'Souza S
    Thromb Haemost; 1976 Aug; 36(1):78-85. PubMed ID: 1087478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma components which interfere with ristocetin-induced platelet aggregation.
    Baugh RF; Brown JE; Hougie C
    Thromb Diath Haemorrh; 1975 Jun; 33(3):540-6. PubMed ID: 1080300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
    Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
    Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.